Plasmacytoid Dendritic Cells Mediate Synergistic Effects of HIV and Lipopolysaccharide on CD27+ IgD− Memory B Cell Apoptosis

Lumin Zhang, a Zhenwu Luo, a Scott F. Sieg, b Nicholas T. Funderburg, c Xiaocong Yu, a Pingfu Fu, a Hao Wu, f Yanmei Jiao, f Yong Gao, b Neil S. Greenspan, d Clifford V. Harding, f J. Michael Kilby, a,h Zhihai Li, g Michael M. Lederman, b Wei Jiang e

Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA; Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, University Hospitals/Case Medical Center, Cleveland, Ohio, USA; School of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, The Ohio State University, Columbus, Ohio, USA; Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts, USA; Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA; Center for Infectious Diseases, Beijing You-An Hospital, Capital Medical University, Beijing, China; Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA; Division of Infectious Diseases, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA

ABSTRACT

The effects of heightened microbial translocation on B cells during HIV infection are unknown. We examined the in vitro effects of HIV and lipopolysaccharide (LPS) on apoptosis of CD27+ IgD− memory B (mB) cells from healthy controls. In vitro analysis was conducted on a cohort of 82 HIV + donors and 60 healthy controls. In vitro exposure of peripheral blood mononuclear cells (PBMCs) to LPS and HIV led to mB cell death via the Fas/Fas ligand (FasL) pathway. Plasmacytoid dendritic cells (pDCs) produced FasL in response to HIV via binding to CD4 and chemokine coreceptors. HIV and LPS increased Fas expression on mB cells in PBMCs, which was dependent on the presence of pDCs and monocytes. Furthermore, mB cells purified from PBMCs and pretreated with both HIV and LPS were more sensitive to apoptosis when co-cultured with HIV-treated pDCs. Blocking the interferon receptor (IFNR) prevented HIV-stimulated FasL production in pDCs, HIV-plus-LPS-induced Fas expression, and apoptosis of mB cells. In vivo or ex vivo, HIV + donors have higher levels of plasma LPS, Fas expression on mB cells, and mB cell apoptosis than controls. Correspondingly, in HIV + donors, but not in controls, a positive correlation was found between plasma FasL and HIV RNA levels and between Fas expression on mB cells and plasma LPS levels. This work reveals a novel mechanism of mB cell apoptosis mediated by LPS and HIV through the Fas/FasL pathway, with key involvement of pDCs and type I IFN, suggesting a role for microbial translocation in HIV pathogenesis.

IMPORTANCE

This study demonstrates that lipopolysaccharide (LPS) and type I interferon (IFN) play an important role in memory B cell apoptosis in HIV infection. It reveals a previously unrecognized role of microbial translocation in HIV pathogenesis.

Perturbations of B lymphocytes in human immunodeficiency virus (HIV) disease include memory B (mB) cell depletion, polyclonal B cell activation, and impaired antibody (Ab) responses after vaccination (1–3). Although some of these deficiencies stem from a lack of CD4+ T cell help, intrinsic B cell dysfunction also appears to be present in HIV disease (4).

Spontaneous B cell apoptosis ex vivo has been observed in both acute and chronic HIV infection (5, 6). Memory B cell depletion may stem from the increased susceptibility of these cells to apoptosis in HIV disease. The tumor necrosis factor alpha (TNF-α)/tumor necrosis factor receptor (TNFR), TRAIL/DR5, Fas/Fas ligand (FasL), and Foxo3a cell death signaling pathways have been reported to play a role in HIV pathogenesis (7–10). Plasmacytoid dendritic cells (pDCs) have been reported to produce TRAIL in response to HIV (mediated through type I interferon [IFN]) and play a role in T cell deletion in HIV infection (11). Additionally, there is evidence of a role for the Fas/FasL signaling pathway in B cell apoptosis in HIV disease (8). Naive B (nB) cells express low levels of Fas, whereas activated mB cells express high levels of Fas (12). However, FasL induction is much more restricted. Previous studies showed that opsonized zymosan, CD4 cross-linking, or HIV in vitro could induce FasL on monocytes or macrophages (13–15). More importantly, inhibition of the Fas/FasL pathway by an anti-FasL Ab (RNOK203) resulted in decreased B cell apoptosis and increased Ab production against viral proteins in simian immunodeficiency virus (SIV)-infected macaques in vivo (16). Furthermore, it was reported that Fas surface expression on B cells from HIV + donors was related to exogenous FasL-induced B cell apoptosis in vitro (8), suggesting that the Fas/FasL signaling pathway is critical for mB cell apoptosis in HIV infection.

Our recent studies indicated that increased microbial translocation from the damaged gut in chronically HIV-infected patients is at least partially responsible for the chronic immune dysregulation observed in HIV-infected patients (17, 18). Toll-like receptors (TLRs), which recognize a wide variety of microbe-associated molecular patterns (MAMPs), play an important role in B cell homeostasis. Microbial products, such as TLR ligands, can maintain mB cell numbers and recall Ab titers in the absence of protein antigens (Ags) in healthy individuals (19). Although TLR ligands released from the gut have long-term effects on the humoral system, they do not appear to maintain mB cell numbers and func-
tions in HIV-infected subjects as they do in healthy subjects (1, 2, 20). However, B cells from HIV-infected subjects are still polyclonally activated and are able to produce auto-Abs during chronic infection (20). Therefore, B cell dysfuntion does not result solely from repeated stimulation by microbial products and subsequent desensitization. We considered the possibility that increased MT in the context of HIV infection might have deleterious effects on B cell function and survival. Given the lack of a direct association between the increased concentrations of microbial products in serum and impaired B cell responses in other chronic diseases associated with heightened MT (e.g., inflammatory bowel disease or chronic hepatitis infection) (21–24), we asked if the concurrent exposure of B cells to microbial products and HIV might contribute to B cell dysfunction during chronic HIV infection. We found that indeed, lipopolysaccharide (LPS) and HIV synergistically induced mB cell apoptosis in a manner that was dependent on pDCs through the Fas/Fasl signaling pathway.

MATERIALS AND METHODS

Study subjects. In the present study, 60 healthy controls, 39 HIV− anti-retroviral therapy (ART)−naive (ART−) patients, and 43 HIV+ ART−treated (ART+) subjects were studied. In order to investigate the effects of HIV and LPS on memory B cell apoptosis, 21% of the ART−treated subjects were viremic. The median CD4 T cell counts and plasma levels of HIV RNA in the ART−treated subjects were 386 cells/μl (interquartile range [IQR], 132 to 607 cells/μl) and 455 cells/μl (IQR, 323 to 565 cells/μl), respectively; in the ART−naive subjects, the median CD4 T cell counts and plasma levels of HIV RNA were 248 copies/ml (IQR, 10 to 493 copies/ml) and 860 copies/ml (IQR, 421 to 1,359 copies/ml), respectively.

Ethics statement. These studies were approved by the Institutional Review Boards for Human Research (IRBs) at the Medical University of South Carolina, Case Western Reserve University, and University Hospita lCases Medical Center of Cleveland. All subjects were adults and provided written informed consent.

Reagents. HIV (CL4/SUPT1, lot number P4509, MN, X4 tropic; CL30/SUPT1, lot number P4101, ADA-M, R5 tropic) was provided by NCI, NIH. HIV−1 gp120 (MN, X4 tropic) was obtained through the Reference Reagent Program, Division of AIDS, NIAID, NIH. LPS was purchased from Sigma (St. Louis, MO), and the CXCR4 inhibitor (CXCRI4inh) (AM31060) was obtained from Sigma. A neutralizing Ab against Fas was obtained from Millipore (Billerica, MA), a neutralizing Ab against IFN receptor was obtained from PBL (Piscataway, NJ), and neutralizing Abs against TNF−α and TRAIL were obtained from R&D Systems (Minneapolis, MN). The IgG1 isotype Ab was purchased from BD Pharmingen (San Jose, CA). FITC and PerCP−Cy5.5 Abs (BD Pharmingen) were purchased from Progenics Pharmaceuticals (New York, NY), and the CCR5 inhibitor (CCRI5inh) maraviroc was obtained from Selzentry (Middlesex, United Kingdom).

Cells. Blood was collected in heparin−coated tubes, and peripheral blood mononuclear cells (PBMCs) were isolated over a Ficoll−Hypaque cushion. The isolated PBMCs were cultured for 30 h in 96−well plates (0.4 × 10^5 cells/200 μl) in fresh complete medium in the presence of bacterial LPS (20 ng/ml; Escherichia coli 0111:B4; Sigma), HIV (150 ng/ml of p24), or both. Fas expression and B cell apoptosis were evaluated by flow cytometry. In some assays, cells were treated with neutralizing Abs (5 μg/ml) against TNF−α; TRAIL; or Fas, Fasl, or both or with the isotype Ab 3 h before adding HIV and LPS. mB cells were tested for annexin V binding, or the cells were treated with soluble CD4 (10 μg/ml), inhibitors of CXCR4 (10 μg/ml), and the IFN receptor inhibitor (20 μg/ml) or the isotype Ab (20 μg/ml) 3 h before adding HIV (X4 or R5 tropic). pDCs were tested for Fasl expression after 20 h by flow cytometry.

Purified B cells were obtained by negative selection (purity, >97%) for B cells; Miltenyi Biotec, Bergisch Gladbach, Germany). pDCs were isolated by negative selection and then positive selection (Diamond pDC isolation kit; purity, >90%; Miltenyi Biotec). Monocyte-depleted, pDC-depleted, or myeloid dendritic cell (MDC−)−depleted PBMCs were obtained using CD14 microbeads, BDCA4 microbeads, or BDCA1 and BDCA3 microbeads, respectively (negative selection; depletion purity, >98%; Miltenyi Biotec).

In coculture assays, purified pDCs were cultured with or without HIV (X4; 150 ng/ml of p24) for 20 h, and PBMCs from the same donor were cultured with medium, LPS, HIV, or both for 20 h. B cells were purified from 20−h−cultured PBMCs under different conditions by positive selection using CD19 microbeads (purity, >90%; Miltenyi Biotec). pDCs and B cells were washed with complete medium and cocultured at a ratio of 1:1 for 3 h. In the transwell system, pDCs were added to the top well, and B cells were added to the bottom well. Annexin V binding among mB cells was measured by flow cytometry.

Cell surface and intracellular staining. For surface staining, Abs were incubated with blood or PBMCs at room temperature for 10 min. After surface staining, the red cells were lysed or the PBMCs were washed and stained intracellularly using Perm/fix reagents (BD) according to the manufacturer’s protocol. The cells were constantly cultured at 37°C after cell permeabilization for Fasl, intracellular staining. After intracellular staining, the cells were immediately analyzed by flow cytometry.

Flow cytometry. The fluorochrome−labeled monoclonal Abs used in this study included Abs against CD95−phycoerythrin (PE) (BD Pharmingen), IgD−PE−Cy7 (Biolegend, San Diego, CA), CD20−peridinin chlorophyll protein (PerCP) (Miltenyi Biotec), CD19−Pacific Blue, CD27−allophycocyanin (APC) (BD Pharmingen), CD38−fluorescein isothiocyanate (FITC) (BD Pharmingen), Fasl−PE (BD Pharmingen), CD123−PerCP−Cy5.5 (Miltenyi Biotec), BDCA2−FITC (Miltenyi Biotec), BDCA1−APC (Miltenyi Biotec), BDCA3−APC (Miltenyi Biotec), CD14−Pacific Blue (BD Pharmingen), CD11c−PE−Cy7 (Biolegend), 7−amino−actinomycin D (7−AAD) (BD), annexin V−FITC (BD Pharmingen), and isotype control Abs (BD Pharmingen). The cells were identified by their forward and side scatter characteristics and were analyzed by flow cytometry on a MACS−Quant flow cytometer (Miltenyi Biotec).

Plasma LPS and Fasl levels. Plasma samples were collected into tubes containing EDTA and stored at −80°C until they were thawed once for analysis of LPS and Fasl. For LPS analysis, the plasma samples were diluted to 10% with endotoxin−free water, and LPS was quantified using a commercially available Limulus amebocyte assay kit (Lonza Inc., Allendale, NJ) according to the manufacturer’s protocol. Plasma Fasl levels were quantified using a commercial kit according to the manufacturer’s protocol (R&D).

Statistical analysis. Conventional measurements of central location and dispersion were used to describe the data, and the differences in continuous measurements between the groups were compared by the Mann−Whitney U test (unpaired) or Wilcoxon matched−paired signed−rank test (paired). To explore associations between pairs of continuous variables, Spearman’s rank correlation was used. Comparison analysis was performed using SPSS software (version 16.01). All tests were 2 sided, and a P value of ≤0.05 was considered to indicate statistical significance.

RESULTS

HIV and LPS synergistically induce CD27+ IgD− mB cell apoptosis in PBMCs in vitro. To evaluate the impact of LPS on mB cell apoptosis in HIV infection, PBMCs were pretreated with medium alone or medium supplemented with LPS, HIV (R5 or X4), and HIV plus LPS. Cell apoptosis was assessed by annexin V and 7−AAD staining in fluorescence−activated cell sorter (FACS)−gated memory (CD19+ CD27+ IgD−) and naive (CD19+ CD27− IgD+) B cells (Fig. 1A). Viable cells (dual negative), early apoptotic cells

Downloaded from http://jvi.asm.org/ on November 13, 2017 by guest
(annexin V positive), and end-stage apoptotic cells and dead cells (dual positive) are shown in Fig. 1A. Because annexin V binding is an indicator of both early- and late-stage apoptosis, only the annexin V staining was used to define apoptotic cells in subsequent assays. These data suggest that costimulation with HIV and LPS induces B cell, and especially mB cell, apoptosis. In contrast, cell-derived control microvesicles (150 ng/ml of protein) did not cooperate with LPS to induce CD27+/H11001 memory B cell death (data not shown). The control microvesicles were isolated from the supernatants of uninfected cell cultures in a manner identical to that of the experimental samples.

FIG 1 mB cell apoptosis in PBMCs is induced by HIV and LPS in vitro. PBMCs were cultured with medium alone (med) or medium supplemented with LPS, HIV (R5 or X4), or both HIV and LPS for 20 h. B cell apoptosis was defined by annexin V binding and 7-AAD among nB (CD27+/H11001 IgD+/H11002) and mB (CD27+/H11001 IgD+/H11002) cells by flow cytometry. (A) Representative dot plots revealing the gating strategy used to assess the frequencies of apoptotic nB and mB cells and the frequencies of early apoptosis (annexin V+/7-AAD−) and late apoptosis (annexin V+/7-AAD+) of nB and mB cells from one representative donor. The numbers represent the frequencies of cells in early apoptosis or late apoptosis among nB or mB cells. FSC, forward scatter; SSC, side scatter. (B to E) Frequencies of B cell subset apoptosis in the presence of LPS and HIV (X4) in different culture systems. (F to I) Frequencies of mB cell apoptosis induced by different treatments in purified B cells. The data are presented as medians. Sample sizes (N) and P values are shown.

FIG 2 mB cell apoptosis induced by HIV and LPS is mediated by pDCs and the Fas/FasL signaling pathway. (A) Frequencies of mB cell apoptosis induced by treatment with medium alone or medium supplemented with LPS, HIV (X4), or LPS plus HIV in pDC-depleted PBMCs. n = 6. P > 0.05 for a comparison between any two treatments. (B) mB cell apoptosis in a coculture of pDCs and B cells. Purified pDCs were incubated with or without HIV (X4) for 20 h. PBMCs were stimulated with medium alone or medium supplemented with LPS, HIV (X4), or LPS plus HIV for 20 h. Total B cells isolated from PBMCs were cocultured with pDCs at a ratio of 1:1. mB cell apoptosis was examined 3 h after coculture. n = 5. (C) mB cell apoptosis in a transwell system with separate culture of pDCs and B cells. Purified pDCs were incubated with or without HIV (X4) for 20 h. PBMCs were stimulated with medium alone or medium supplemented with LPS, HIV (X4), or LPS plus HIV for 20 h. Total B cells (bottom wells) isolated from PBMCs were separately cocultured with pDCs (top wells) at a ratio of 1:1 in a transwell system to prevent direct cell-to-cell contacts. mB cell apoptosis was examined 3 h after coculture. n = 7. P > 0.05 for comparisons between any two conditions. (D) Cytotoxicity of pDCs on Fas-expressing Jurkat cells. PBMCs were cultured with medium or HIV (X4) for 20 h, and then stimuli were removed. pDCs were isolated and cocultured with Fas-expressing Jurkat cells at 3 h, and the percentage of apoptosis in Jurkat cells (CD4+/H11001) was tested by flow cytometry. n = 5. (E) PBMCs were incubated with neutralizing Abs against TNF-α, TRAIL, Fas, Fasl, both Fas and Fasl, or a control isotype IgG1 for 3 h before adding HIV (X4) and LPS. The frequency of mB cell apoptosis was measured after 20 h of incubation. n = 9. The data are presented as medians.
FIG 3 Fas expression on mB cells is induced by HIV plus LPS via pDCs and monocytes. (A) (Left) Representative dot plots displaying the gating strategy used to assess the percentage of surface Fas expression on mB cells from one representative donor. (Right) Median percentages of Fas expression on mB cells after 24 h of treatment with medium alone or medium supplemented with LPS, HIV (X4), or both HIV and LPS. *n = 20.* (B) PBMCs from control donors were treated with medium or HIV (X4) plus LPS. The correlation between apoptotic mB cell induction (% annexin V+) and Fas-positive mB cell induction (% Fas+) by treatment with HIV (X4) plus LPS was analyzed after the subtraction of control medium values. *n = 15.* (C) PBMCs were cultured with medium or HIV (X4) plus
used for virus preparation from infected cells. Moreover, the effect of LPS on mB cell death was dose dependent in vitro. A concentration of LPS (200 pg/ml) comparable to what has been measured in HIV-infected viremic patients (17) was found to have a modest effect on mB cell death. Increasing the LPS concentration to 20 ng/ml had a significant effect on mB cell death; therefore, we used 20 ng/ml to investigate the impact of LPS on mB apoptosis in subsequent assays.

To further evaluate the effects of HIV virions and LPS on CD27+ IgD+ mB cell apoptosis, PBMCs were cultured in medium, LPS (20 ng/ml), HIV (X4 or R5; 150 ng/ml of p24), or both HIV and LPS for 30 h. A combination of HIV (R5) and LPS caused significant apoptosis of both nB and mB cells, but not plasma cells (Fig. 1B to D). Since mB cell depletion has been extensively observed in HIV infection (26), to clarify the impacts of HIV and LPS on mB cell apoptosis, we purified B cells from PBMCs. Interestingly, mB cell apoptosis induced by HIV plus LPS was observed only in whole PBMCs and not in purified B cells (Fig. 1E). A similar effect on mB cell apoptosis in PBMCs was observed in the combination of HIV (X4) and LPS, but not in purified B cells (Fig. 1F to I), indicating that mB cell apoptosis requires the presence of other non-B cells in PBMCs.

mB cell apoptosis in response to HIV and LPS requires pDCs acting through the Fas/FasL pathway. pDCs have been implicated in B cell growth and differentiation (27). To investigate whether pDCs are involved in mB cell apoptosis induced by LPS and HIV, pDCs were depleted from PBMCs in the apoptosis assay. Intriguingly, depletion of pDCs abrogated the synergistic effect of HIV (X4) and LPS on mB cell apoptosis (Fig. 2A), indicating that pDCs participated in the regulation of mB cell apoptosis. This point was corroborated by the restoration of mB cell apoptosis after coculturing HIV-plus-LPS-treated B cells with HIV-treated pDCs (Fig. 2B). Cell-to-cell contact is required for this effect (Fig. 2B and C). Furthermore, apoptosis was induced in Fas-expressing Jurkat cells by HIV-treated pDCs (Fig. 2D), raising the possibility of pDC involvement through the Fas/FasL pathway. Indeed, the introduction of a soluble-FasL inhibitor or Fas inhibitor significantly reduced mB cell apoptosis in response to HIV plus LPS (Fig. 2E). Blocking TNF-α and TRAIL with neutralizing Abs also had a significant effect (Fig. 2E). In the current study, we focused on Fas/FasL, the main cell death pathway mediating HIV- and LPS-induced mB cell apoptosis.

Next, to verify the contribution of Fas expression to mB apoptosis in response to HIV plus LPS, PBMCs were cultured with medium alone or medium supplemented with LPS, HIV (X4), and HIV plus LPS for 24 h, as shown in Fig. 3A. Fas expression on mB cells was induced by HIV plus LPS compared to medium, HIV, or LPS alone. Moreover, HIV-plus-LPS-induced Fas expression on mB cells was directly associated with HIV-plus-LPS-induced mB apoptosis (Fig. 3B). Indeed, HIV-plus-LPS-activated B cells were more susceptible to apoptosis induced by FasL-expressing KFL9 cells (Fig. 3C). Human monocytes express TLR4 (28) and are supposed to be involved in mB apoptosis via direct interaction between TLR4 and LPS. Depletion of pDCs and monocytes induced a remarkable inhibition of Fas induction on HIV-plus-LPS-treated mB cells (Fig. 3D). Additionally, a neutralizing Ab against interferon receptor (IFNR) prevented Fas induction on mB cells by HIV and LPS (Fig. 3E), and a neutralizing Ab against TNF-α reduced Fas induction on mB cells by HIV and LPS (Fig. 3F), suggesting that HIV-plus-LPS-induced Fas expression on mB cells is driven by multiple pathways and that type I IFN is one of the most important mediators. Furthermore, inhibition of type I IFNR reduced mB cell apoptosis by HIV and LPS (Fig. 3G), confirming that type I IFN is critical for mB cell apoptosis in response to HIV and LPS through the Fas/FasL pathway.

To further address the role of pDCs in Fas/FasL-mediated mB cell apoptosis, we first assessed soluble FasL in the PBMC culture supernatants with medium, LPS, HIV (X4), or HIV plus LPS and did not detect any significant changes in soluble-FasL expression in the supernatants from PBMCs cultured under various conditions (Fig. 4A). To further confirm the pDC effect, whole PBMCs were cultured with HIV (X4 or R5 tropic) and HIV gp120 protein (MN, X4 tropic) with or without sCD4, the CXCR4 or CCR5 inhibitors, and the neutralizing Ab against IFNR. FasL intracellular expression in pDCs was examined after 20 h of cultivation. The data showed that HIV (X4 and R5; 150 ng/ml of p24) and HIV gp120 protein (X4; 150 ng/ml) induced intracellular FasL expression in pDCs. sCD4 and CXCR4inh or CCR5inh significantly decreased FasL induction by pDCs in response to HIV (Fig. 4B and C). Furthermore, neutralizing Abs against IFNR inhibited the induction of FasL on pDCs by HIV (Fig. 4B and C). In contrast, there was no significant change in intracellular FasL expression in monocytes or MDCs in response to HIV (data not shown). Direct ex vivo analysis of pDCs, MDCs, and monocytes revealed that HIV-infected subjects displayed increased frequencies of intracellular FasL expression compared to healthy donors only in pDCs (and not in monocytes or MDCs) (Fig. 4D). Moreover, the percentage of FasL+ pDCs was directly related to plasma HIV RNA levels (Fig. 4E). These results suggest that Fas/FasL pathway-mediated mB cell apoptosis is dependent on pDCs and IFN.

Collectively, these data suggest that pDCs are essential for the synergistic effect of HIV and LPS on mB cell apoptosis. CD4, the HIV coreceptor, and type I IFN are responsible for the induction of FasL in pDCs.

HIV infection is associated with increases in Fas expression on mB cells, plasma LPS, and apoptosis of mB cells. To address whether the synergistic effect of HIV and LPS contributes to mB cell apoptosis in vivo, we next examined levels of LPS, Fas/FasL expression, and mB cell apoptosis in plasma of healthy controls and HIV+ donors. High levels of plasma LPS were detected in HIV+ donors, particularly in ART-naive HIV+ donors (Fig. 5A). Accordingly, increased frequencies of mB cell...
FIG 4 HIV activates pDCs to produce FasL. (A) PBMCs were cultured with medium, LPS, HIV (X4), or LPS plus HIV for 24 h. FasL production in the supernatants was measured by enzyme-linked immunosorbent assay (ELISA) *in vitro*. *n = 5. P > 0.05 for a comparison between any two treatments. (B) Representative dot plots displaying the gating strategy used to assess the percentage of FasL+ in pDCs from one representative donor. PBMCs were first treated with sCD4 (10 μg/ml), IFNR inhibitor (20 μg/ml), CXCR4 inhibitor (AMD3100; 10 μg/ml), or CCR5 inhibitor (10 μg/ml) for 3 h and then incubated with medium, HIV (X4, 150 ng/ml, or R5, 150 ng/ml), or gp120 (150 ng/ml) for an additional 20 h. The intracellular levels of FasL in pDCs (CD123+ BDCA2+) were analyzed by flow cytometry. (C) Median frequencies of FasL+ pDCs and P values between pairs of conditions. (D) The frequencies of intracellular FasL expression were examined in monocytes (CD14+), MDCs (BDCA1/3+ CD11c+), and pDCs (CD123+ BDCA2+) from 4 controls and 5 viremic ART-naive HIV+ donors in fresh peripheral blood samples *ex vivo*. (E) Correlation between the percentages of FasL+ pDCs and plasma HIV RNA levels. The data are presented as medians.
apoptosis in freshly isolated PBMCs were observed in ART-naive HIV+ donors (Fig. 5B). Moreover, Fas expression on mB cells in HIV+ donors, particularly ART-naive HIV+ donors, was higher than that on control cells (Fig. 5C and D). No significant difference in plasma FasL among healthy controls and two groups of HIV+ donors was found (Fig. 5E). These data indicate that HIV infection is associated with increased plasma LPS levels, higher Fas expression on mB cells, and increased mB cell apoptosis.

Fas expression on mB cells positively correlates with plasma LPS levels, and plasma FasL levels are highly associated with plasma HIV RNA levels among HIV+ donors. To further investigate the interactions between LPS, plasma HIV RNA, and mB cell apoptosis in vivo, we quantified each of these parameters in ART-naive healthy controls and HIV+ donors. The results revealed that there was a significant correlation between plasma LPS levels and Fas expression on mB cells ($r = 0.38; P < 0.001$) (Fig. 6A) in HIV+ donors but not in HIV− controls ($r = -0.24; P = 0.13$) (Fig. 6B). There was no positive relationship between plasma LPS levels and plasma FasL levels in HIV− and HIV+ donors (Fig. 6C and D). In contrast, a significant correlation was obtained between plasma HIV RNA levels and plasma soluble-FasL levels in HIV+ donors ($r = 0.56; P < 0.0001$) (Fig. 6E). A correlation between Fas expression on mB cells and plasma HIV RNA levels was noted ($r = 0.35; P = 0.01$) (Fig. 6F). These results suggest that in HIV+ donors, Fas surface expression on mB cells might be partially induced by heightened levels of LPS and HIV replication, whereas FasL production is mediated by HIV infection per se.

DISCUSSION

Several mechanisms have been proposed to contribute to mB cell depletion and dysfunction in HIV disease, including impaired CD4 T cell help, direct viral binding to B cells through CD21 (29) or through integrin $\alpha 4\beta 7$ (30), polyclonal B cell activation (3), perturbations in B cell trafficking and differentiation (31), and impaired function of T follicular helper cells (32, 33). B cell dys-function can lead to loss of the ability to control microbial translocation at mucosal sites due to inadequate levels of mucosal IgA (34). In the present study, we found that HIV and LPS exert a synergistic effect in inducing the apoptosis of CD27+ IgD− mB cells, suggesting that MT could play an important role in mB cell apoptosis during chronic HIV infection.

Microbial TLR agonists are important factors in maintaining normal immune function (19). Sterile conditions cause immunodeficiency in mice (35). However, long-term exposure to microbial TLR ligands (likely also including HIV-derived components serving as TLR7/8 ligands) may induce persistent immune activation and perturbation of B cell function, manifested as hyperimmunoglobulinemia or a reduced ability to produce Ag-specific
Abs in HIV disease. However, it is clear that patients with other diseases also characterized by heightened MT can exhibit polyclonal B cell activation in the absence of increasing B cell apoptosis and depletion. Chronic hepatitis B infection is such an example (37–40). Nonpathogenic animal models also do not exhibit a “leaky” gut or heightened levels of MT (17, 41) during chronic SIV infection. Consistently, HIV infection is associated with increased levels of FasL in pDCs, in pDCs in HIV infection. Moreover, we did not find that soluble CD4 and a coreceptor inhibitor reduced FasL by pDCs could induce mB cell apoptosis in a transwell system (Fig. 4D). The suppression of FasL in pDCs and decreased Fas expression on mB cells caused by an IFN inhibitor in vitro suggest a cascade of mB cell apoptosis via interferon secretion and FasL production from pDCs in HIV infection. Moreover, we did not find that soluble Fasl by pDCs could induce mB cell apoptosis in a transwell system (Fig. 2D), implying that direct cell-to-cell communication between pDCs and mB cells is required for mB cell apoptosis. HIV gp120 contains binding regions for CD4 and the HIV coreceptor and has been shown to induce significant FasL expression via cellular receptors (48). Consistent with this information, gp120-induced more FasL expression in pDCs than HIV (Fig. 4 Band C). Nevertheless, there was no difference in the plasma FasL levels in ART donors (Fig. 2D) (A) and HIV donors (n = 53) (B), (C and D) Correlation analysis between plasma LPS levels and FasL in HIV donors (n = 38) (C) and HIV donors (n = 27 and n = 14) (D). (E and F) Correlation analysis between plasma HIV RNA levels and plasma FasL levels (n = 30 and n = 16) (E) or between plasma levels of HIV RNA and Fas expression on mB cells in HIV donors (n = 41 and n = 27) (F). The open circles represent ART-naive HIV donors, and the solid circles represent ART-treated HIV donors.

FIG 6 Fas/FasL expression was associated with plasma LPS and HIV RNA levels in HIV donors in vivo or ex vivo. (A and B) Correlation analysis between plasma LPS levels and Fas expression on mB cells in HIV donors (r = 0.38, P = 0.003) (A) and HIV donors (r = 0.21, P = 0.20) (B). (C and D) Correlation analysis between plasma LPS levels and Fas expression on mB cells in HIV donors (r = 0.38) (C) and HIV donors (r = 0.38) (D). (E and F) Correlation analysis between plasma HIV RNA levels and plasma FasL levels (r = 0.50, P < 0.0001) (E) or between plasma levels of HIV RNA and Fas expression on mB cells in HIV donors (r = 0.33, P = 0.01) (F).
infection mediate mB cell apoptosis through the Fas/FasL pathway in vivo. The concentrations of HIV and LPS used in this study were higher than physiological doses, calling into question this effect in vivo; however, lymph nodes from HIV-infected patients exhibit heightened levels of inflammation and virus replication compared to the periphery (49), and the amounts of virus and LPS in contact with pDCs and mB cells in lymph nodes may be much greater than their concentrations in plasma, suggesting that this effect may contribute to mB cell apoptosis in vivo.

Our results suggest a model to explain humoral immune dysregulation mediated by HIV infection and microbial products (Fig. 7). HIV infection results in the increased apoptosis of gut epithelial cells and the depletion of Th17 cells, which permits MT from the damaged gut (50, 51). As a consequence of MT, TLR ligands stimulate B cells and induce polyclonal activation, as reflected in the increased levels of auto-Abs in HIV infection (52). Our data show that TLR ligands also increase the sensitivity of mB cells to apoptosis through pDCs and IFN. However, HIV infection plays a central role in this model by virtue of its ability to induce apoptotic signals via the persistent production of inflammatory factors, such as IFN and FasL.

In summary, we have uncovered a novel mechanism for mB cell apoptosis in HIV attributable to the synergistic activities of viral infection and LPS. This synergistic effect was at least in part mediated by the Fas/FasL apoptotic pathway via pDCs. Our findings provide new insight into mechanisms of B cell dysfunction during chronic HIV infection and suggest that blocking MT in HIV-infected patients might be a useful therapeutic strategy to inhibit the perturbation of humoral immunity.

ACKNOWLEDGMENTS

We thank the Bad Boys of Cleveland/Cleveland Immunopathogenesis Consortium (AI076174) for helpful comments and discussions related to this project.

This work was supported by NIH grants AI91526, AI034343, and AI6219; by a STERIS grant; and by the National 12th Five-Year Plan in China (2012ZX10001-003 and 2012ZX10001-006), the Beijing Municipal Science and Technology Commission (D09030703590901), and the Beijing Key Laboratory (BZ00089). This study utilized facilities and resources of the Center for Oral Health Research (COHR) at Medical University of South Carolina, which is supported by National Institute of General Medicine grant P30GM103331.

REFERENCES


